Did the FDA make the right call on propoxyphene?
This article was originally published in Scrip
Executive Summary
The decision by the US FDA at long last to pull propoxyphene-containing products from the US market (scripintelligence.com, 22 November 2010) has been greeted by the full gamut of responses, from those alleging it is part of a plot to force patients to use newer, more expensive medications to those who claim that the ruling is part of the Obama administration’s scheme to exert ever greater control over the individual.